Inspire Sleep Apnea Innovation - Obstructive Sleep Apnea Treatment (2024)

FAQs

What is the downside to Inspire sleep? ›

Besides surgical risks, some people may experience discomfort or unpleasant side effects from the Inspire sleep apnea device. These may be sensations like dry mouth, tongue discomfort, or feeling aware of the device.

A securities fraud class action complaint alleges that Inspire Medical misled investors and/or failed to disclose that: (1) despite the Acceleration Program, customers were encountering challenges with the prior authorization submission process, including with the scheduling of appointments; (2) a slowdown in prior ...

Inspire implant: Most insurance plans cover this, and it's also available at some Veterans Affairs and military hospitals. CareCredit reports the price of a hypoglossal-nerve stimulator like Inspire as $30,000 to $40,000 if you self-pay.

Inspire Upper Airway Stimulation (UAS) is an FDA approved treatment for people with moderate to severe Obstructive Sleep Apnea (OSA) who are unable to use or get consistent benefit from CPAP. Inspire therapy works inside the body with a patient's natural breathing process.

Contraindications for the use of Inspire implant include the following: Central + mixed apneas >25% of the total apnea-hypopnea index (AHI) Any anatomical finding that would compromise the performance of upper airway stimulation, such as the presence of complete concentric collapse of the soft palate.

The actual implant is designed to last a lifetime. However, it operates on a battery that lasts approximately ten to twelve years.

Once the therapy is turned on, some patients may experience discomfort from stimulation, tongue abrasion, mouth dryness, and discomfort from the presence of the device. The majority of these events are resolved either on their own, with medication, or by adjusting the therapy settings.

If you are a good candidate for the procedure, about 70% to 80% of patients will get significant improvement, where we see moderate to severe sleep apnea improve down to at least a mild range. About a third of patients can achieve full control of their sleep apnea with Inspire.

Under the financial-loss settlement, users are entitled to a $100 award if they return their recalled device by Aug. 9, 2024 — the claim deadline. People who suspect they own or use one of the affected devices should act soon to verify that if they haven't already, the FDA says.

Inspire therapy has been clinically tested for people with a body mass index (BMI) up to 40. Over 90% ¹ of U.S. adults are within this range. Most insurance policies have a BMI policy in place for Inspire therapy coverage. Talk to your provider or Inspire therapy-trained doctor for more information.

What is the new pill for sleep apnea? ›

Apnimed is a company that's developed a new oral drug for sleep apnea – currently called AD109. AD109 combines the drugs aroxybutynin and atomoxetine. Aroxybutynin is used to treat symptoms of an overactive bladder, while atomoxetine is used to treat attention deficit hyperactivity disorder.

Inspire is reimbursed by most major insurance providers, either as a covered policy or approved on an individual basis. Your doctor and the insurance team at Inspire will work with you for approval.

Data indicate that the Inspire device reduces sleep apnea by an average of 79% and significantly reduces snoring and daytime sleepiness.

Generally, no. However, you should ask your doctor about any activities that are particularly strenuous (e.g., weightlifting) or that entail a large or unpredictable range of motion of your upper body and/or arms (e.g., working as a firefighter).

The most common side effects of Inspire include soreness or tenderness at the implant site, throat pain, and temporary weakness in the tongue. These side effects are usually mild and go away on their own. Serious side effects are rare, but can include infection, bleeding, and nerve damage.

For example, Inspire therapy is not intended for patients with a complete concentric collapse at the level of the soft palate, or those in whom central and mixed apneas make up 25% or more of their apnea-hypopnea index.